M&A / Deals Alzecure enters collaboration and with Lilly for Alzheimer’s project PharmaTimesPartnership grants Lilly global rights to Alzstatin ACD680NeuroscienceRead full story pharminent June 9, 2026 (Last updated: June 9, 2026) PharmaTimes Partnership grants Lilly global rights to Alzstatin ACD680 Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill dataNext: Cancer biotech Parabilis books record IPO, raising $670m Related Stories M&A / Deals Zymeworks cuts deal to buy Theravance for $929m in cash pharminent June 29, 2026 M&A / Deals Ipsen charts $1.75bn course for Kartos acquisition pharminent June 29, 2026 M&A / Deals Immunai and Boehringer partner to identify T-cell targets pharminent June 26, 2026
